Upstream Bio, Inc. (NASDAQ:UPB - Get Free Report) shares gapped down before the market opened on Wednesday . The stock had previously closed at $10.31, but opened at $10.05. Upstream Bio shares last traded at $10.21, with a volume of 9,719 shares.
Analyst Upgrades and Downgrades
Separately, Wall Street Zen upgraded shares of Upstream Bio from a "sell" rating to a "hold" rating in a research report on Friday, June 6th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $56.50.
Read Our Latest Report on UPB
Upstream Bio Price Performance
The company has a 50-day moving average price of $9.30 and a 200-day moving average price of $10.93.
Upstream Bio (NASDAQ:UPB - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.02). The company had revenue of $0.57 million for the quarter, compared to analyst estimates of $0.71 million. As a group, sell-side analysts anticipate that Upstream Bio, Inc. will post -4.3 EPS for the current fiscal year.
Institutional Trading of Upstream Bio
A number of institutional investors and hedge funds have recently made changes to their positions in UPB. FMR LLC purchased a new stake in Upstream Bio during the fourth quarter worth approximately $117,977,000. Orbimed Advisors LLC acquired a new position in shares of Upstream Bio during the 4th quarter valued at $93,603,000. Decheng Capital LLC purchased a new stake in Upstream Bio during the 4th quarter worth $54,010,000. TCG Crossover Management LLC acquired a new stake in Upstream Bio in the 4th quarter valued at $44,856,000. Finally, Enavate Sciences GP LLC acquired a new stake in Upstream Bio in the 4th quarter valued at $40,438,000.
About Upstream Bio
(
Get Free Report)
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Upstream Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Upstream Bio wasn't on the list.
While Upstream Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
